Phase I clinical trial repurposing all-trans retinoic acid as a stromal targeting agent for pancreatic cancer

Pre-clinical models have shown that targeting pancreatic stellate cells with all-trans-retinoic-acid (ATRA) reprograms pancreatic stroma to suppress pancreatic ductal adenocarcinoma (PDAC) growth. Here, in a phase Ib, dose escalation and expansion, trial for patients with advanced, unresectable PDAC...

Descripción completa

Detalles Bibliográficos
Autores principales: Kocher, Hemant M., Basu, Bristi, Froeling, Fieke E. M., Sarker, Debashis, Slater, Sarah, Carlin, Dominic, deSouza, Nandita M., De Paepe, Katja N., Goulart, Michelle R., Hughes, Christine, Imrali, Ahmet, Roberts, Rhiannon, Pawula, Maria, Houghton, Richard, Lawrence, Cheryl, Yogeswaran, Yathushan, Mousa, Kelly, Coetzee, Carike, Sasieni, Peter, Prendergast, Aaron, Propper, David J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7518421/
https://www.ncbi.nlm.nih.gov/pubmed/32973176
http://dx.doi.org/10.1038/s41467-020-18636-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7518421/
https://www.ncbi.nlm.nih.gov/pubmed/32973176
http://dx.doi.org/10.1038/s41467-020-18636-w

Ejemplares similares